

# 知っておきたいエビデンス一覧

本欄は、p.904～944の各薬剤における「知っておきたいエビデンス」他の文献情報を一覧化したものです。(以下、URLはすべて2018年6月11日現在)

## 乳がん

### 01 ノルバデックス® (タモキシフェン)

- 1) Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al : Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen ; patient-level meta-analysis of randomised trials. Lancet **378** (9793) : 771-784, 2011. PMID 21802721
- 2) Davies C, et al : Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer ; ATLAS, a randomised trial. Lancet **381**(9869) : 805-816, 2013. PMID 23219286

### 02 アリミデックス® (アナストロゾール)

- 1) Cuzick J, et al (ATAC/LATTE investigators) : Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer ; 10-year analysis of the ATAC trial. Lancet Oncol **11**(12) : 1135-1134, 2010. PMID 21087898

### 03 リュープリン® (リュープロレリン)

- 1) Suzuki K, et al : Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients ; a Phase III, randomized, open-label, parallel-group, comparative study in Japan. Jpn J Clin Oncol **45**(12) : 1168-1174, 2015. PMID 26486824
- 2) Akaza H, et al : Efficacy of primary hormone therapy for localized or locally advanced prostate cancer ; results of a 10-year follow-up. BJU Int **98**(3) : 573-579, 2006. PMID 16925756

### 04 ティーエスワン® (テガフル・ギメラシル・オテラシルカリウム)

- 1) Sakuramoto S, et al : Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med **357**(18) : 1810-1820, 2007. PMID 17978289
- 2) Koizumi W, et al : S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) ; a phase III trial. Lan-

cet Oncol **9**(3), 215-221, 2008. PMID 18282805

- 3) Yamada Y, et al : Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol **26**(1) : 141-148, 2015. PMID 25316259

### 05 オブジーボ® (ニボルマブ)

- 1) Robert C, et al : Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med **372**(4) : 320-330, 2015. PMID 25399552
- 2) Brahmer J, et al : Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med **373**(2) : 123-135, 2015. PMID 26028407
- 3) Puzanov I, et al : Managing toxicities associated with immune checkpoint inhibitors ; consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer **5**(1) : 95, 2017. PMID 29162153
- 4) Hida T, et al : Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci **108**(5) : 1000-1006, 2017. PMID 28266091
- 5) 日本肺癌学会 : 肺癌診療ガイドライン 2017 年版, 2017.  
[https://www.haigan.gr.jp/modules/guideline/index.php?content\\_id=3](https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3)
- 6) 小野薬品工業株式会社 : 非小細胞肺癌の適正使用ガイド. 安全性・適正使用情報. オブジーボ. jp, 2017.  
[https://www.opdivo.jp/drug\\_info\\_files/drug\\_info/opdivo/tekisei/20000156/guide\\_nsccl.pdf](https://www.opdivo.jp/drug_info_files/drug_info/opdivo/tekisei/20000156/guide_nsccl.pdf)
- 7) 厚生労働省 : ニボルマブ (遺伝子組換え) 製剤の最適使用推進ガイドライン (非小細胞肺癌). 2017.
- 8) Brahmer JR, et al : Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy ; American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol JCO2017776385, 2018. PMID 29442540

## 膀胱がん

## 前立腺がん

## 胃がん

9) 日本臨床腫瘍学会 (編) : がん免疫療法ガイドライン. 金原出版, 2016.

## 06| ジェムザール® (ゲムシタビン)

1) Burris HA 3rd, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer ; a randomized trial. J Clin Oncol **15**(6) : 2403-2413, 1997. PMID 9196156

2) Ueno H, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan ; GEST study. J Clin Oncol **31**(13) : 1640-1608, 2013. PMID 23547081

3) Janus N, et al : Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol **21**(7) : 1395-403, 2010. PMID 20118214

## 07| スーテント® (スニチニブ)

1) Motzer RJ, et al : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med **356**(2) : 115-124, 2007. PMID 17215529

## 08| グリベック® (イマチニブ)

1) O'Brien SG, et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med **348**(11) : 994-1004, 2003. PMID 12637609

2) Marin D, et al : Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol **28**(14) : 2381-2388, 2010. PMID 20385986

3) Mahon FX, et al : Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years ; the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol **11**(11) : 1029-1035, 2010. PMID 20965785

小児夜尿症

関節リウマチ

## 09| ミニリンメルト® (デスモプレシン)

1) Glazener CM, et al : Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev (3) : CD002112, 2002. PMID 12137645

2) Fjellestad-Paulsen A, et al : Comparison of intranasal and oral desmopressin for nocturnal enuresis. Arch Dis Child **62**(7) : 674-677, 1987. PMID 3307643

3) 日本夜尿症学会 (編) : 夜尿症診療ガイドライン 2016, 診断と治療社, 2016.

## 10| リウマトレックス® (メトトレキサート)

1) Shea B, et al : Folic acid or folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol **41**(6) : 1049-1060, 2014. PMID 24737913

2) Kameda T, et al : Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res **66**(9) : 1302-1309, 2014. PMID 24515570

3) 日本リウマチ学会 : 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2016 年改訂版【簡易版】. 羊土社, 2016. <https://www.ryumachi-jp.com/publication/pdf/MTX2016kanni.pdf>

## 11| シンボニー® (ゴリムマブ)

1) Emery P, et al : Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis ; twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum **60**(8) : 2272-2283, 2009. PMID 19644849

2) Rubbert-Roth A, et al : TNF inhibitors in rheumatoid arthritis and spondyloarthritis ; Are they the same? Autoimmun Rev **17**(1) : 24-28, 2018. PMID 29108829

腎がん

慢性骨髄性白血病

**12| エビリファイ® (アリピプラゾール)**

1) Leucht S, et al : Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis. *Lancet* **382**(9896) : 951-962, 2013. PMID 23810019

**13| リーマス® (リチウム)**

1) BALANCE investigators and collaborators, et al : Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE) ; a randomised open-label trial. *Lancet* **375**(9712) : 385-395, 2010. PMID 20092882

2) Hayes JF, et al : Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment ; A UK Population-Based Electronic Health Records Study. *JAMA Psychiatry* **73**(6) : 630-637, 2016. PMID 27167638

3) Ehret MJ, et al : Long-term use of atypical antipsychotics in bipolar disorder. *Pharmacotherapy* **26**(8) : 1134-1147, 2006. PMID 16863489

**14| エクセグラン® (ゾニサミド)**

1) 清野昌一, 他 : AD-810 (zonisamide) の薬効評価. *医学のあゆみ* **144**(4) : 275-291, 1988.

2) Murata M, et al : Zonisamide has beneficial effects on Parkinson's disease patients. *Neurosci Res* **41**(4) : 397-399, 2001. PMID 11755227

**15| ニュープロ® パッチ (ロチゴチン)**

1) Trenkwalder C, et al (RECOVER Study Group) : Rotigotine effects on early morning motor function and sleep in Parkinson's disease ; a double-blind, randomized, placebo-controlled study (RECOVER). *Mov Disord* **26**(1) : 90-99, 2011. PMID 21322021

2) Nomoto M, et al : Correction to ; Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly ; a post hoc analysis of randomized, double-blind, placebo-controlled trials. *J Neurol* **265**(2) : 266-272, 2018. PMID 29270687

3) Wüllner U, et al (NEUPOS Study Group) : Transdermal rotigotine for the perioperative management of Parkinson's disease. *J Neural Transm (Vienna)* **117**(7) : 855-859, 2010. PMID 20535621

**16| テビケイ® (ドルテグラビル)**

1) Günthard HF, et al : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults ; 2016 Recommendations of the International Antiviral Society-USA Panel. *JAMA* **316**(2) : 191-210, 2016. PMID 27404187

2) Obel N, et al : Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART ; a population-based nationwide cohort study. *PLoS One* **6**(7) : e22698, 2011. PMID 21799935

**17| デシコビ® (エムトリシタビン・テノホビル アラフェナミド)**

1) Günthard HF, et al : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults ; 2016 Recommendations of the International Antiviral Society-USA Panel. *JAMA* **316**(2) : 191-210, 2016. PMID 27404187

2) Obel N, et al : Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART ; a population-based nationwide cohort study. *PLoS One* **6**(7) : e22698, 2011. PMID 21799935

3) 関東甲信越 HIV/AIDS 情報ネット : 医療費軽減のために. 制度のてびき.  
<http://kkse-net.jp/tebiki01.html>

**18| ネオーラル® (シクロスポリン)**

1) Umezawa Y, et al : Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis. *Int J Dermatol* **46**(8) : 880-882, 2007. PMID 17651179

2) Ito T, et al : Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin micro-emulsion therapy. *J Dermatol* **41**(5) : 377-381, 2014. PMID 24628433

3) Vena GA, et al : Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis ; a randomized controlled open-label study. *J Dermatolog Treat* **23**(4) : 255-260, 2012. PMID 21756153

緑内障

## 19 | ダイアモックス® (アセタゾラミド)

- 1) Scozzafava A, et al : Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem **75** : 349–359, 2014. PMID 24146387
- 2) Sridharan K, et al : Pharmacological interventions for preventing acute mountain sickness ; a network meta-analysis and trial sequential analysis of randomized clinical trials. Ann Med **50**(2) : 147–155, 2018. PMID 29166795
- 3) Smith SV, et al : The Idiopathic Intracranial Hypertension Treatment Trial ; A Review of the Outcomes. Headache **57**(8) : 1303–1310, 2017, PMID 28758206
- 4) 澤口 昭一 : 炭酸脱水酵素阻害薬 (内服含む ; 配合剤含まず). あたらしい眼科 **29**(4) : 467–472, 2012.

## 20 | ダクルインザ® (ダクラタスビル)

- 1) Kumada H, et al : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology **59**(6) : 2083–2091, 2014. PMID 24604476
- 2) Manns M, et al : All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b ; multinational, phase 3 trial, multicohort study. Lancet **384** (9954) : 1597–1605, 2014. PMID 25078304
- 3) Toyota J, et al : Daclatasvir/asunaprevir/sofosbuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol **52**(3) : 385–395, 2017. PMID 27502287

## 21 | スンベプラ® (アスナプレビル)

- 1) Manns M, et al : Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2) ; a randomised, double-blind, placebo-controlled phase 3 trial. Lancet **384**(9941) : 414–426, 2014. PMID 24907224

## 22 | ソバルディ® (ソホスブビル)

- 1) Mizokami M, et al : Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C ; an open-label, randomised, phase 3 trial. Lancet Infect Dis **15**(6) : 645–653, 2015. PMID 25863559

B型肝炎

- 2) Omata M, et al : Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection : an open-label, phase 3 trial. J Viral Hepat **21**(11) : 762–768, 2014. PMID 25196837
- 3) Asahina Y, et al : Ledipasvir–sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int doi: 10.1111/liv.13685, 2018. PMID 29297980
- 4) Gane EJ, et al : Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med **368**(1) : 34–44, 2013. PMID 23281974

## 23 | バラクルード® (エンテカビル)

- 1) Lai CL, et al : Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med **354**(10) : 1011–1020, 2006. PMID 16525138
- 2) Chang TT, et al : A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med **354**(10) : 1001–1010, 2006. PMID 16525137
- 3) Ozaras R, et al : First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment. Eur J Gastroenterol Hepatol **26**(7) : 774–780, 2014. PMID 24901822

## 24 | プレマリン® (結合型エストロゲン)

- 1) MacLennan AH, et al : Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev (4) : CD002978, 2004. PMID 15495039
- 2) Anderson GL, et al : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy ; the Women's Health Initiative randomized controlled trial. JAMA **291**(14) : 1701–1712, 2004. PMID 15082697
- 3) Rossouw JE, et al : Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA **297**(13) : 1465–1477, 2007. PMID 17405972
- 4) 日本産科婦人科学会・日本産婦人科医会 (編・監修) : ホルモン補充療法ガイドライン 2017. 日本産科婦人科学会, 2017.

更年期障害

C型肝炎

**25| ピレスパ® (ピルフェニドン)**

- 1) Raghu G, et al : An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ; treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med **192**(2) : e3-19, 2015. PMID 26177183
- 2) King TE Jr, et al : A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med **370**(22) : 2083-2092, 2014. PMID 24836312
- 3) Nathan SD, et al. : Effect of pirfenidone on mortality ; pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med **5**(1) : 33-41, 2017. PMID 27876247

**26| エフィエント® (プラスグレル)**

- 1) Wiviott SD, et al : Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med **357**(20) : 2001-2015, 2007. PMID 17982182
- 2) Saito S, et al : Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome ; the PRASFIT-ACS study. Circ J **78**(7) : 1684-1692, 2014. PMID 24759796
- 3) Valgimigli M, et al : 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS ; The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J **39**(3) : 213-260, 2018. PMID 28886622

**27| エリキューズ® (アピキサバン)**

- 1) Granger CB, et al : Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med **365**(11) : 981-992, 2011. PMID 21870978
- 2) Halvorsen S, et al : Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation ; observations from the ARISTOTLE trial. Eur Heart J **35**(28) : 1864-1872, 2014. PMID 24561548
- 3) Shields AM, et al : Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med **278**(1) : 1-18, 2015. PMID 25758241

- 4) Raccach BH, et al : Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure ; Systematic Review and Meta-Analysis of Randomized Trials. Chest **149**(6) : 1516-1524, 2016. PMID 26836922

**28| サムスカ® (トルバプタン)**

- 1) 筒井裕之, 他 : 急性・慢性心不全診療ガイドライン (2017年改訂版). 日本循環器学会・日本心不全学会, 2018.
- 2) Gheorghiade M, et al : Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure ; the EVEREST Clinical Status Trials. JAMA **297**(12) : 1332-1343, 2007. PMID 17384438
- 3) Shirakabe A, et al : Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J **78**(4) : 911-921, 2014. PMID 24553192
- 4) Watanabe K, et al : Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol **60**(6) : 462-469, 2012. PMID 23068288

**29| アンカロン® (アミオダロン)**

- 1) Roy D, et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med **358**(25) : 2667-2677, 2008. PMID 18565859
- 2) Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators : A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med **337**(22) : 1576-1583, 1997. PMID 9411221
- 3) Connolly SJ, et al : Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators ; the OPTIC Study ; a randomized trial. JAMA **295**(2) : 165-171, 2006. PMID 16403928
- 4) AFFIRM First Antiarrhythmic Drug Substudy Investigators : Maintenance of sinus rhythm in patients with atrial fibrillation ; an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol **42**(1) : 20-29, 2003. PMID 12849654

5) Marrouche NF, et al : Catheter ablation for atrial fibrillation with heart failure. N Engl J Med **378**(5) : 417-427, 2018. PMID 29385358

### 30 | ジャディアンス®(エンパグリフロジン)

- 1) Zinman B, et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med **373**(22) : 2117-2128, 2015. PMID 26378978
- 2) Neal B, et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med **377**(7) : 644-657, 2017. PMID 28605608

### 31 | ビクトーザ®(リラグルチド)

- 1) Seino Y, et al : Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin **26**(5) : 1013-1022, 2010. PMID 20199137
- 2) Kaku K, et al : Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab **12**(4) : 341-347, 2010. PMID 20380655
- 3) Marso SP, et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med **375**(4) : 311-322, 2016. PMID 27295427

### 32 | リファジン®(リファンピシン)

- 1) Karumbi J et al : Directly observed therapy for treating tuberculosis. Cochrane Database Systematic Review (5) : CD003343, 2015. PMID 26022367

### 33 | イスコチン® | ヒドラ(イソニアジド)

- 1) Smieja MJ, et al : Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev (2) : CD001363, 2000. PMID 10796642
- 2) Kunst H, et al : Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection ; a systematic review. Int J Tuberc Lung Dis **14**(11) : 1374-1381, 2010. PMID 20937175
- 3) 日本結核病学会 : 結核診療ガイドライン. 南江堂, 2015.

### 34 | ピラマイド®(ピラジナミド)

- 1) Sharma SK, et al : Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis **50**(6) : 833-839, 2010. PMID 20156055
- 2) 日本結核病学会 : 結核診療ガイドライン. 南江堂, 2015.

### 35 | エサンブトール® | エブトール® | (エタンブトール)

- 1) Lee EJ, et al : Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuroophthalmol **28**(4) : 269-277, 2008. PMID 19145123
- 2) 日本結核病学会 : 結核診療ガイドライン. 南江堂, 2015.

### 36 | フォルテオ®(テリパラチド)

- 1) Nevitt MC, et al : Reduced risk of back pain following teriparatide treatment ; a meta-analysis. Osteoporos Int **17**(2) : 273-280, 2006. PMID 16142502
- 2) Saag KG, et al : Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med **357**(20) : 2028-2039, 2007. PMID 18003959
- 3) 日本骨粗鬆症学会, 日本骨代謝学会, 骨粗鬆症財団 : 骨粗鬆症の予防と治療ガイドライン 2015 年版. ライフサイエンス出版, 2015.
- 4) Qaseem A, et al : Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women ; A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med **166**(11) : 818-839, 2017. PMID 28492856

### 37 | ミルセラ®(エポエチン ベータ ペゴル)

- 1) Tsubakihara Y, et al : High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial **16**(6) : 529-540, 2012. PMID 23190512
- 2) Evans M, et al : Initiation of erythropoiesis-stimulating agents and outcomes ; a nationwide observational cohort study in anaemic chronic kidney disease patients. Nephrol Dial Transplant **32**(11) : 1892-1901, 2017. PMID 27672090

### 38| バイアグラ® (シルデナフィル)

1) Eardley I, et al : Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol **53**(Suppl 1) : 61S-65S, 2002. PMID 11879261

2) 押野見和彦, 他 : クエン酸シルデナフィル治療における自尊心の評価—自尊心とパートナーの間柄に関する質問票を用いて. 日本性機能学会雑誌 **24**(3) : 339-348, 2009.

### 39| エルネオパ® NF (糖・電解質・アミノ酸・総合ビタミン・微量元素液)

1) Cozzaglio L, et al : Outcome of cancer patients receiving home parenteral nutrition. Italian Society of Parenteral and Enteral Nutrition (S.I.N.P.E.). JPEN J Parenter Enteral Nutr **21**(6) : 339-342, 1997. PMID 9406131

2) Morita T, et al : Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies. Ann Oncol **16**(4) : 640-647, 2005. PMID 15684225

### 40| セレジスト® (タルチレリン)

1) 金澤一郎, 他 : Taltirelin hydrate (TA-0910) の脊髄小脳変性症に対する臨床評価—プラセボを対照とした臨床第Ⅲ相二重盲検比較試験. 臨床医薬 **13**(16) : 4169-4224, 1997.